Anticipating the Availability of Retatrutide Despite its exciting trial results, Retatrutide is only expected to reach the market by 2028, pending FDA approval
A recent Survey of Ophthalmology review synthesized findings from cardiovascular outcomes trials, retrospective database analyses, meta-analyses and preclinical studies involving semaglutide, liraglutide, dulaglutide and related agents across six ocular conditions: diabetic retinopathy (DR), glaucoma, nonarteritic anterior ischemic optic neuropathy (NAION), age-related macular degeneration (AMD), idiopathic intracranial hypertension (IIH) and dry eye disease (DED)
Acteoside protects against 6-OHDA-induced dopaminergic neuron damage via Nrf2-ARE signaling pathway
The trajectories look different
How Tirzepatide Stacks Up Against Testosterone Men treated with tirzepatide: Lost an average of 8.1% of their body weight , compared to just 2.4% with lifestyle intervention and 3.0% with testosterone therapy
Metformin and reduced risk of cancer in diabetic patients